Hazard rates of recurrence following diagnosis of primary breast cancer

被引:78
作者
Jatoi, I
Tsimelzon, A
Weiss, H
Clark, GM
Hilsenbeck, SG
机构
[1] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA
[2] Natl Naval Med Res Inst, Dept Surg, Bethesda, MD USA
[3] Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA
[4] OSI Pharmaceut Inc, Boulder, CO USA
关键词
breast cancer; hazard functions; hazard rates; recurrence; survival;
D O I
10.1007/s10549-004-1722-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We calculated hazard rates for recurrence in patients with primary breast cancer ( stage I, II; no adjuvant therapy). Previous publications have indicated a peak in hazard rates for recurrence ( or death) at approximately 2-3 years after diagnosis of primary breast cancer. However, there have been conflicting reports concerning the presence of a second peak at 5-7 years after diagnosis. In this study, we estimated hazard functions by the Nelson-Aalen method and fit by cubic-linear and cubic-cubic-linear models to test for the presence of one or two peaks, respectively. We identified two peaks in hazard of recurrence, one at 2 years and another at 5 years. The 5-year peak, though statistically significant, represents very small differences in patient outcome. This additional peak may be an artifact of interval censoring due to a tendency to follow-up patients at specific bench-mark time points.
引用
收藏
页码:173 / 178
页数:6
相关论文
共 25 条
[1]  
Baum M, 1994, BREAST CANC CONTROVE, P61
[2]  
COLLETT D, 2003, MODELLING SURVIVAL D, P33
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: Further support about the concept of tumor dormancy [J].
Demicheli, R ;
Abbattista, A ;
Miceli, R ;
Valagussa, P ;
Bonadonna, G .
BREAST CANCER RESEARCH AND TREATMENT, 1996, 41 (02) :177-185
[5]   Menopausal status dependence of early mortality reduction due to diagnosis of smaller breast cancers (T1 v T2-T3):: Relevance to screening [J].
Demicheli, R ;
Bonadonna, G ;
Hrushesky, WJM ;
Retsky, MW ;
Valagussa, P .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :102-107
[6]   Double-peaked time distribution of mortality for breast cancer patients undergoing mastectomy [J].
Demicheli, R ;
Valagussa, P ;
Bonadonna, G .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 75 (02) :127-134
[7]   Comparative analysis of breast cancer recurrence risk for patients receiving or not receiving adjuvant cyclophosphamide, methotrexate, fluorouracil (CMF). Data supporting the occurrence of 'cures' [J].
Demicheli, R ;
Miceli, R ;
Brambilla, C ;
Ferrari, L ;
Moliterni, A ;
Zambetti, M ;
Valagussa, P ;
Bonadonna, G .
BREAST CANCER RESEARCH AND TREATMENT, 1999, 53 (03) :209-215
[8]   Dormancy of mammary carcinoma after mastectomy [J].
Demicheli, R ;
Miceli, R ;
Valagussa, P ;
Bonadonna, G .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (04) :347-348
[9]   FLEXIBLE REGRESSION-MODELS WITH CUBIC-SPLINES [J].
DURRLEMAN, S ;
SIMON, R .
STATISTICS IN MEDICINE, 1989, 8 (05) :551-561
[10]   Development of angiogenesis inhibitors for cancer therapy [J].
Eckhardt, SG ;
Pluda, JM .
INVESTIGATIONAL NEW DRUGS, 1997, 15 (01) :1-3